Search PeptideClear
Peptides, vetted UK sellers, or GLP-1 clinics. Pick a tab below.
Try a quick search
We have not vetted that site yet.
PeptideClear can audit this source for you for free. Editorial verdict within 72 hours.
Got it. Editorial verdict within 72 hours.
We will email you a link to the published /retailer/[slug]/ profile once the audit lands.
While you wait, 3 already-vetted alternatives
Alternatives are matched to your stated goal. We earn nothing if you click through, and the links carry no tracking. How we are funded.
Regulatory tracker
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last reviewed: 2026-08-11
The MHRA published 24 items in the 90 days to 2026-08-11, of which 2 relate to weight-loss medicines or peptides, 3 concern enforcement against illegal or unlicensed supply, and 4 are formal Drug Safety Updates. This page restates what the regulator published and links to each gov.uk original. It is a reporting record, not advice. If a medicine you take appears in a Drug Safety Update, the item itself tells you what the MHRA asks patients and prescribers to do, and your prescriber or pharmacist is the person to speak to.
24
MHRA items in the window
2
Relevant to this site
3
Enforcement actions
4
Drug Safety Updates
The subset that touches the categories this site covers. Everything else the regulator published in the same window is in the full table below.
As with all GLP-1 receptor agonists, the MHRA will keep the safety and effectiveness of orforglipron under close review.
Read the MHRA original on gov.ukAs demand for weight-loss medicines continues to rise, the MHRA is reminding people how to use GLP-1 medicines safely, spot illegal sellers, and avoid diet changes that could interfere with their medicines.
Read the MHRA original on gov.ukEverything the MHRA published between 2026-05-20 and 2026-08-10, newest first. We list the full record rather than only the convenient parts, so the selection above can be checked against what was actually published.
| Date | Type | Item | Relevant to weight-loss medicines or peptides |
|---|---|---|---|
| 2026-08-10 | Announcement | UK first in Europe to authorise orforglipron for weight management and type 2 diabetes | Yes |
| 2026-08-10 | Announcement | MHRA advises quarantine of medical devices supplied without appropriate conformity markings | No |
| 2026-08-07 | Announcement | Taking medication this summer? What you need to know about sun and heat exposure | No |
| 2026-08-06 | Announcement | MHRA approves remibrutinib for adults with chronic spontaneous urticaria | No |
| 2026-08-04 | Announcement | The Innovative Licensing and Access Pathway grants Innovation Passports to investigational products for cancer and dementia | No |
| 2026-07-30 | Announcement | Pioneering AI health innovations regulatory sandbox launched | No |
| 2026-07-30 | Announcement | Thousands of patients to benefit from new daily pill for serious heart condition following co-ordinated MHRA and NICE decisions | No |
| 2026-07-29 | Announcement | Beat the heat: MHRA urges people to take extra care with medical devices this summer | No |
| 2026-07-29 | Announcement | MHRA clarifies regulatory status of ambient voice technologies used in the NHS | No |
| 2026-07-24 | Enforcement | No summer shortcut for safe weight loss | Yes |
| 2026-07-21 | Announcement | MHRA approves world's first lower-carbon beclometasone inhalers for patients with asthma | No |
| 2026-07-21 | Drug safety update | Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension | No |
| 2026-07-17 | Announcement | Hot cars, hot luggage: why where you store your medicines matters this summer | No |
| 2026-07-16 | Announcement | MHRA delivers record performance as 2025-26 Annual Report and Accounts confirms growing global influence | No |
| 2026-07-15 | Drug safety update | Botulinum toxin type A products: updated warnings regarding risk of iatrogenic botulism | No |
| 2026-07-15 | Announcement | UK-donor plasma given go-ahead for new medicines | No |
| 2026-07-15 | Enforcement | Updated warnings for botulinum toxin products following rare cases of botulism | No |
| 2026-07-10 | Announcement | Yellow Cards: bad in football; brilliant in patient safety | No |
| 2026-07-09 | Announcement | Heat, travel and late nights: How summer can affect your medicines and how to stay safe | No |
| 2026-07-08 | Announcement | Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis | No |
| 2026-07-08 | Enforcement | Four sentenced to nearly 15 years combined jail time following major MHRA investigation into illegal online supply of medicines | No |
| 2026-07-06 | Announcement | MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer | No |
| 2026-06-16 | Drug safety update | ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly | No |
| 2026-05-20 | Drug safety update | Amiodarone: reminder of risks of treatment and need for patient monitoring and supervision | No |
Source: gov.uk MHRA announcements feed and MHRA Drug Safety Update feed
### MHRA items published in the 90 days to 2026-08-11, by date and type | Date | Type | Item | Relevant to weight-loss medicines or peptides | | --- | --- | --- | --- | | 2026-08-10 | Announcement | UK first in Europe to authorise orforglipron for weight management and type 2 diabetes | Yes | | 2026-08-10 | Announcement | MHRA advises quarantine of medical devices supplied without appropriate conformity markings | No | | 2026-08-07 | Announcement | Taking medication this summer? What you need to know about sun and heat exposure | No | | 2026-08-06 | Announcement | MHRA approves remibrutinib for adults with chronic spontaneous urticaria | No | | 2026-08-04 | Announcement | The Innovative Licensing and Access Pathway grants Innovation Passports to investigational products for cancer and dementia | No | | 2026-07-30 | Announcement | Pioneering AI health innovations regulatory sandbox launched | No | | 2026-07-30 | Announcement | Thousands of patients to benefit from new daily pill for serious heart condition following co-ordinated MHRA and NICE decisions | No | | 2026-07-29 | Announcement | Beat the heat: MHRA urges people to take extra care with medical devices this summer | No | | 2026-07-29 | Announcement | MHRA clarifies regulatory status of ambient voice technologies used in the NHS | No | | 2026-07-24 | Enforcement | No summer shortcut for safe weight loss | Yes | | 2026-07-21 | Announcement | MHRA approves world's first lower-carbon beclometasone inhalers for patients with asthma | No | | 2026-07-21 | Drug safety update | Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension | No | | 2026-07-17 | Announcement | Hot cars, hot luggage: why where you store your medicines matters this summer | No | | 2026-07-16 | Announcement | MHRA delivers record performance as 2025-26 Annual Report and Accounts confirms growing global influence | No | | 2026-07-15 | Drug safety update | Botulinum toxin type A products: updated warnings regarding risk of iatrogenic botulism | No | | 2026-07-15 | Announcement | UK-donor plasma given go-ahead for new medicines | No | | 2026-07-15 | Enforcement | Updated warnings for botulinum toxin products following rare cases of botulism | No | | 2026-07-10 | Announcement | Yellow Cards: bad in football; brilliant in patient safety | No | | 2026-07-09 | Announcement | Heat, travel and late nights: How summer can affect your medicines and how to stay safe | No | | 2026-07-08 | Announcement | Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis | No | | 2026-07-08 | Enforcement | Four sentenced to nearly 15 years combined jail time following major MHRA investigation into illegal online supply of medicines | No | | 2026-07-06 | Announcement | MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer | No | | 2026-06-16 | Drug safety update | ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly | No | | 2026-05-20 | Drug safety update | Amiodarone: reminder of risks of treatment and need for patient monitoring and supervision | No | Source: gov.uk MHRA announcements feed and MHRA Drug Safety Update feed
“A rolling window is honest but it is not history. Items drop off this page after ninety days, so an absence here means the MHRA has not published on it recently, not that nothing has ever been published. Read the enforcement rows as evidence that illegal supply is actively prosecuted in the UK, and read a quiet period as ordinary rather than as reassurance about any particular seller.”
Last fetched 2026-08-11. PeptideClear is editorial. We do not prescribe, dispense or sell medicines.
PeptideClear is editorial. Nothing here replaces the regulator, and you should not take our word for any of it. These are the official UK destinations where the underlying position is published, free to read and open to anyone.
MHRA
MHRA Products portalThe Summary of Product Characteristics and Patient Information Leaflet for every medicine licensed in the UK. This is the authoritative document for what a medicine is licensed to do.
MHRA
Drug Safety UpdateThe MHRA monthly bulletin of safety advice for prescribers and patients. Where new risks and product information changes are formally announced.
MHRA
Report a fake or illegally supplied medicineThe MHRA route for reporting a website or seller supplying medicines illegally, and for reporting a product you believe is counterfeit.
Advertising Standards Authority
CAP Code and ASA rulingsThe UK advertising rules, including the ban on advertising prescription-only medicines to the public, and the published rulings that show how they are applied.
World Anti-Doping Agency
WADA Prohibited ListThe annually updated list of substances and methods banned in sport. Many research peptides sit under S0 or S2. UK Anti-Doping enforces it on tested athletes.
legislation.gov.uk
Human Medicines Regulations 2012The legislation that defines what counts as a medicine in the UK, and what constitutes illegal supply. A product marketed with medicinal claims is regulated as a medicine regardless of how it is labelled.
PeptideClear maintains these as refreshable datasets rather than one-off articles. Each carries its own source, methodology and last-updated date.
Live data tracker
UK GLP-1 prescribing tracker →
Monthly NHS England primary-care prescribing volumes for GLP-1 medications, rebuilt as each new month publishes. Dated chart, month-by-month table, full methodology.
Source: NHSBSA English Prescribing Dataset
Live data tracker
UK peptide clinical-trials tracker →
Registered interventional trials for every research peptide we track, by phase and recruitment status, linking through to each compound record.
Source: ClinicalTrials.gov and ISRCTN
Live data tracker
UK peptide regulation: monthly overview →
A monthly record combining the MHRA feed with a web-search pass for ASA rulings, Trading Standards action and named-retailer enforcement, each item linked to its source.
Source: gov.uk / MHRA / ASA / Trading Standards
Live data tracker
UK research-peptide price index →
Headline price per milligram across the UK research-peptide retailers we score, so a price can be read against the market rather than in isolation.
Source: PeptideClear retailer survey
Live data tracker
PeptideClear Trust Index →
159 UK sellers scored on six observable certificate-of-analysis signals, free and independently, on the Which? Trusted Traders / Checkatrade model. Every signal reproducible from the published data.
Source: PeptideClear methodology
Live data tracker
Data API and MCP server →
Read-only, no-auth REST API and MCP server over the full scored dataset: corporate identity, regulatory status, CoA verification signals. CC BY 4.0.
Source: PeptideClear, live data
PeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). All services, operations and publications under the PeptideClear brand are delivered by Best Business Loans Ltd.
Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates.
Operates under UK data protection and consumer standards, including UK GDPR.
Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.